Mehmet Altan

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone, William N. William, Annikka Weissferdt et al. · Nature Medicine · 2021 · 582 citations · Full text

Neostar Trial, Medicine, Immune Checkpoint Inhibitor +6

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan et al. · Nature Medicine · 2018 · 443 citations · Full text

Tumor Biology, Oncology, Kinase Inhibitor +12

Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Giulia C. Leonardi, Justin F. Gainor, Mehmet Altan et al. · Journal of Clinical Oncology · 2018 · 351 citations · Full text

Apoptosis, Immunology, Immunoediting +20

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Amir Vajdi et al. · Journal of Thoracic Oncology · 2021 · 346 citations · Full text

Tumor Biology, Programmed Death-, Medicine +10

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

Esther Aguilar, Biagio Ricciuti, Justin F. Gainor et al. · Annals of Oncology · 2019 · 318 citations